Generalized Anxiety Disorder – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis – Generalized Anxiety Disorder (US)
The use of pharmacotherapies for the treatment of generalized anxiety disorder (GAD) has grown sharply, fueled by an increasing prevalence of the disorder and constrained access to nonpharmacologic options. The GAD market is highly genericized, and the first lines of therapy (SSRI and SNRI antidepressants) are well tolerated, effective against anxiety and comorbid depression, and affordable. Nevertheless, only 60-85% of patients respond to current agents, only half of whom achieve remission; thus, patients must often resort to adjunctive therapy or progress to alternate therapies. Therefore, despite the genericization of early lines of therapy, brands emerge rapidly in subsequent lines of treatment for GAD and opportunities persist for more-effective anxiolytics, particularly with a faster onset of action than the current first lines of treatment. This report is critical for developers to appreciate the potential of novel therapies entering this market, the rate at which newly diagnosed patients progress to branded therapies, and the degree of spillover use of multiple therapies as PCPs and psychiatrists attempt to treat GAD and its comorbidities.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed GAD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed GAD patients?
- How has Takeda / Lundbeck’s Trintellix been integrated into the treatment algorithm, and what is its source of business?
- What percentage of GAD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of GAD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Lundbeck, Otsuka Pharmaceuticals, Takeda Pharmaceuticals, Sumitomo Dainippon Pharma / Sunovion, Intra-Cellular Therapies
Key drugs: Rexulti, Trintellix, Latuda, Savella, Fetzima, Vraylar, Viibryd, Fanapt, Caplyta
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Table of contents
Andrea S. Witt, Ph.D., is Director of the Central Nervous System and Ophthalmology Disorders Portfolio at Clarivate, where she oversees a team of Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.
Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.